Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - AbbVie
 More »

  • AbbVie Expands Galapagos Collaboration to Include Crohn's Disease
    AbbVie and Galapagos said today they will extend their potential billion-dollar-plus ... to occur in the second quarter of 2015-AbbVie will pay Galapagos $50 million, then fund ...
    5-17-2013
  • Pharma Touting Phase II/III Wins in Run-Up to ASCO
    ... also present Phase II safety and efficacy results on elotuzumab plus lenalidomide and low-dose dexamethasone in patients with relapsed multiple myeloma, along with partner AbbVie. ...
    5-16-2013
  • Biotechs Need to Walk the Walk on Drug Value
    ... Two months later, 10 pharma giants-AbbVie, AstraZeneca (AZ), Boehringer Ingelheim, Bristol-Myers Squibb (BMS), GlaxoSmithKline, Johnson & Johnson, Lilly, Pfizer, Roche, and ...
    5-15-2013
  • AbbVie, Alvine Make $70M Celiac Disease Drug Deal
    of at least some relief in the future: AbbVie is collaborating with celiac disease ... Under the deal, AbbVie will make an initial up-front payment of $70 million for an ...
    5-14-2013
  • Chicago Plans Biotech Commercialization Center
    Several of them are either based in suburbs of Chicago, such as Abbott Laboratories and its new prescription-drug spinoff AbbVie; or have U.S. headquarters in the region, such as ...
    4-24-2013
  • E&Y: Biotechs Must Walk the Walk on Drug Value
    Two months later, 10 pharma giants-AbbVie, AstraZeneca (AZ), Boehringer Ingelheim, Bristol-Myers Squibb (BMS), GlaxoSmithKline, Johnson & Johnson, Lilly, Pfizer, Roche, and ...
    4-22-2013
  • Biosimilars: 10 Drugs to Watch
    ... 2012 sales: $9.265 billion (AbbVie) 3 Patent status: Patent set to expire 2016 in U.S.; 2018 in EU Neulasta (pegfilgrastim) Drug developers: Hospira: Biosimilar in development. ...
    4-22-2013
  • CEO Perks
    ... compensation, $3.097 million; Option awards, just under $3 million Richard A. Gonzalez AbbVie, chairman and CEO 5 Perks and "all other" compensation: $449,288, consisting of: ...
    4-12-2013
  • Receptos Licenses AbbVie Antibody for Co-Development
    Receptos agreed to license a humanized anti-interleukin-13 (IL-13) antibody from AbbVie, ... FDA-designated orphan disease indication. AbbVie holds an exclusive option to enter into a ...
    3-13-2013
  • Top 20 Best-Selling Drugs of 2012
    ... $1.428 billion J&J + $0.511 billion Merck & Co.] #1. Humira (adalimumab) Drug maker: AbbVie 9 Indication(s): Moderate to severe rheumatoid arthritis, moderate to severe chronic ...
    3-1-2013
  • Galapagos Deals Aim to Shore Up Drug Discovery
    A month after submitting an Investigational New Drug application for its lead candidate to the FDA, Belgian-owned small molecule and antibody discoverer Galapagos moved to ...
    1-15-2013
  • AbbVie Spins Off from Abbott
    Abbott Laboratories today spun off its branded biopharmaceutical operations into AbbVie, ... research in immunology-R&D that AbbVie is expected to continue since the ...
    1-2-2013
  • On Eve of AbbVie Spinoff, Abbott Axes 550
    proprietary drug development operations into a new company, to be named AbbVie, on January 1, 2013. AbbVie is forecast to generate $18 billion in sales next year; its best-selling ...
    10-18-2012
  • Life Tech, SGC Creating Master Set of Epigenetics Antibodies
    SGC is a nonprofit organization involving 200 researchers at the University of Toronto, and University of Oxford (U.K.), together with six pharmaceutical companies: AbbVie, Eli ...
    7-19-2012
  • Abbott Expects Spinoff AbbVie to Be a $17.4B Proprietary Drug...
    The new spinout, to be called AbbVie, will be a $17.444 billion powerhouse whose ... Except for Humira, "AbbVie believes that no single patent, license, trademark (or related ...
    6-7-2012

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll